Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, LSOG Bld. Room 305, 333 Cedar Street, PO Box 208063, New Haven, CT, 06520-8063, USA.
Curr Oncol Rep. 2021 Apr 14;23(6):61. doi: 10.1007/s11912-021-01052-8.
This review aims to summarize the current immunotherapy studies and the potential targeted therapies showing promise in the treatment of cervical cancer.
There are promising ongoing monotherapy and combination therapy trials using different immune checkpoint inhibitors, poly adenosine diphosphate ribose polymerase inhibitors, tumor angiogenesis inhibitors (i.e., bevacizumab), antibody-drug conjugates, therapeutic vaccines, and tumor-infiltrating T lymphocytes (adoptive immunotherapy). Some of these novel modalities are also being evaluated in combination with standard platinum-based chemotherapy regimen. At this time, pembrolizumab is approved for the treatment of relapsed or metastatic programmed death ligand 1 (PD-L1) positive cervical cancer after frontline chemotherapy treatment. Multiple novel therapeutic modalities are emerging as safe and effective for the treatment of cervical cancer patients. Development and participation in investigative treatments can provide benefit and improve outcomes in cervical cancer.
本文旨在总结目前在宫颈癌治疗中显示出前景的免疫治疗研究和潜在的靶向治疗。
目前正在进行使用不同免疫检查点抑制剂、多聚腺苷二磷酸核糖聚合酶抑制剂、肿瘤血管生成抑制剂（如贝伐珠单抗）、抗体药物偶联物、治疗性疫苗和肿瘤浸润 T 淋巴细胞（过继免疫疗法）的单药和联合治疗试验。其中一些新方法也在与标准铂类化疗方案联合评估。目前，派姆单抗被批准用于一线化疗后复发或转移性程序性死亡配体 1（PD-L1）阳性宫颈癌的治疗。多种新的治疗方法已被证明对宫颈癌患者的治疗安全有效。开发和参与探索性治疗可以为宫颈癌患者带来益处并改善其预后。
